Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
A recent study found that transplanting such kidneys and then treating the recipient for hep C worked well.
People without hep C received kidney, liver or heart transplants from HCV-positive donors and then were treated for the virus.
Taking Vemlidy rather than Viread as prophylaxis against hepatitis B is tied to better markers of kidney and bone health.
Among those who switched their hep B treatment, Vemlidy may also be tied to a higher chance of ALT liver enzyme normalization.
In a recent study of Gilead’s Epclusa (sofosbuvir/velpatasvir), 92 percent of participants were on dialysis and 29 percent had cirrhosis.
Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.
Researchers crunched the numbers for transplanting kidneys from donors with hep C and then treating the virus in the recipient.
Conditions such as autoimmune disorders, insulin resistance and cardiovascular disease tend to have a better outlook.
Nevertheless, researchers advise careful kidney monitoring when pairing the medications.
That’s according to a recent computer model that predicted that transplanting such kidneys first and treating the virus later is efficient.
Additionally, in a recent study, having hep C mutations associated with resistance didn’t affect the outcome of treatment.
Whether you have hepatitis C or not, everyone needs to know how to take care of their kidneys.
Compared with their HIV-negative peers, HIV-positive individuals have higher rates of treatment for a host of health problems.
A recent study analyzed kidney parameters among those with HIV who were treated for hep C with the regimen.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.